Integra LifeSciences Holdings Corporation (IART)
After hours:
| Previous close | 28.85 |
| Open | 28.66 |
| Bid | 29.24 x 600 |
| Ask | 29.29 x 600 |
| Day's range | 28.66 - 29.42 |
| 52-week range | 22.36 - 46.75 |
| Volume | |
| Avg. volume | 1,134,787 |
| Market cap | 2.305B |
| Beta (5Y monthly) | 1.17 |
| PE ratio (TTM) | 57.35 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap
- GlobeNewswire
Integra LifeSciences to Present at the 2024 Bank of America Healthcare Conference
PRINCETON, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that Lea Knight, chief financial officer will present at the 2024 Bank of America Healthcare conference on Tuesday, May 14, 2024 at 4:40pm ET. A live webcast of the presentation will be available on the Integra LifeSciences investor relations website at http://investor.integralife.com/events-and-presentations. About Integra LifeS
- GlobeNewswire
Integra LifeSciences Reports First Quarter 2024 Financial Results
PRINCETON, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2024. First Quarter 2024 Highlights First quarter revenues of $368.9 million declined 3.1% on a reported basis and declined 2.5% on an organic basis compared to the prior year. Revenue increased 1.6% on an organic basis excluding BostonFirst quarter GAAP earnings per diluted
